Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes

Basit Öğe Kaydı
dc.contributor.authorEsin, Ece
dc.contributor.authorÇakmak Öksüzo?lu, Berna
dc.contributor.authorBilici, Ahmet Erkan
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorKöstek, Osman
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorAksoy, Sercan
dc.contributor.authorAktaş, Burak Yasin
dc.contributor.authorÖzdemir, Özlem
dc.contributor.authorAlacacıoğlu, Ahmet
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorSümbül, Ahmet Taner
dc.contributor.authorSakin, Abdullah
dc.contributor.authorPaydaş, Semra
dc.contributor.authorYetişir, Ersin
dc.contributor.authorEr, Özlem
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorYıldırım, Nilgün
dc.contributor.authorŞakalar, Teoman
dc.contributor.authorDemir, Hacer
dc.contributor.authorArtaç¸, Mehmet
dc.contributor.authorKaraa?aç, Mustafa
dc.contributor.authorHarputluo?lu, Hakan
dc.contributor.authorBilen, Ebru
dc.contributor.authorErdur, Erkan
dc.contributor.authorDe?irmencio?lu, Serkan
dc.contributor.authorAliyev, Altay
dc.contributor.authorÇil, Timuçin
dc.contributor.authorOlgun, Polat
dc.contributor.authorBaşaran, Gül Atalay
dc.contributor.authorGümüşay, Özge
dc.contributor.authorDemir, Atakan
dc.contributor.authorTanrıkulu, Eda
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorİmamoğlu, İnanç
dc.contributor.authorOyan, Başak
dc.contributor.authorÇetin, Bülent Eren
dc.contributor.authorHaksöyler, Veysel
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorErtürk, İsmail
dc.contributor.authorEvrensel, Türkkan
dc.contributor.authorYılmaz, Hasan
dc.contributor.authorBeypınar, İsmail
dc.contributor.authorKoçer, Murat
dc.contributor.authorPilancı, Kezban Nur
dc.contributor.authorŞeker, Mesut Metin
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorYıldırım, Nuriye O.
dc.contributor.authorEren, Tülay
dc.contributor.authorDemirci, Umut
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:58Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:58Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000458407200014
dc.descriptionPubMed ID: 30377778
dc.description.abstractPurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.
dc.identifier.citationEsin, E., Çakmak Öksüzoğlu, B., Bilici, A. E., Çiçin, İ., Köstek, O., Kaplan M. A. … Demirci, U. (2019). Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes. Cancer Chemotherapy and Pharmacology, 83(1), 131-143. https://dx.doi.org/10.1007/s00280-018-3712-7
dc.identifier.doi10.1007/s00280-018-3712-7
dc.identifier.endpage143
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue1
dc.identifier.scopusqualityQ1
dc.identifier.startpage131
dc.identifier.urihttps://dx.doi.org/10.1007/s00280-018-3712-7
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2118
dc.identifier.volume83
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectPertuzumab
dc.subjectTrastuzumab
dc.subjectAntiher2
dc.subjectVisceral Metastasis
dc.subjectBrain Metastasis
dc.titlePertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Bilici, Ahmet Erkan.pdf
Boyut:
1.07 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu